Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NR1H2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NR1H2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NR1H2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NR1H2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NR1H2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003497625 | Esophagus | HGIN | response to endoplasmic reticulum stress | 81/2587 | 256/18723 | 1.47e-13 | 2.32e-11 | 81 |
GO:190589725 | Esophagus | HGIN | regulation of response to endoplasmic reticulum stress | 31/2587 | 82/18723 | 5.25e-08 | 2.91e-06 | 31 |
GO:003133425 | Esophagus | HGIN | positive regulation of protein-containing complex assembly | 61/2587 | 237/18723 | 7.10e-07 | 3.00e-05 | 61 |
GO:004325427 | Esophagus | HGIN | regulation of protein-containing complex assembly | 94/2587 | 428/18723 | 2.39e-06 | 8.55e-05 | 94 |
GO:190495120 | Esophagus | HGIN | positive regulation of establishment of protein localization | 73/2587 | 319/18723 | 6.99e-06 | 2.14e-04 | 73 |
GO:190357320 | Esophagus | HGIN | negative regulation of response to endoplasmic reticulum stress | 18/2587 | 44/18723 | 8.97e-06 | 2.64e-04 | 18 |
GO:003052220 | Esophagus | HGIN | intracellular receptor signaling pathway | 62/2587 | 265/18723 | 1.63e-05 | 4.50e-04 | 62 |
GO:005123520 | Esophagus | HGIN | maintenance of location | 73/2587 | 327/18723 | 1.73e-05 | 4.71e-04 | 73 |
GO:005122220 | Esophagus | HGIN | positive regulation of protein transport | 67/2587 | 303/18723 | 5.13e-05 | 1.22e-03 | 67 |
GO:003166726 | Esophagus | HGIN | response to nutrient levels | 89/2587 | 474/18723 | 1.41e-03 | 1.64e-02 | 89 |
GO:00483844 | Esophagus | HGIN | retinoic acid receptor signaling pathway | 11/2587 | 31/18723 | 2.02e-03 | 2.12e-02 | 11 |
GO:004586126 | Esophagus | HGIN | negative regulation of proteolysis | 68/2587 | 351/18723 | 2.21e-03 | 2.28e-02 | 68 |
GO:00028325 | Esophagus | HGIN | negative regulation of response to biotic stimulus | 25/2587 | 108/18723 | 5.87e-03 | 4.77e-02 | 25 |
GO:0034976111 | Esophagus | ESCC | response to endoplasmic reticulum stress | 192/8552 | 256/18723 | 7.15e-22 | 1.30e-19 | 192 |
GO:0043254111 | Esophagus | ESCC | regulation of protein-containing complex assembly | 278/8552 | 428/18723 | 3.81e-16 | 2.77e-14 | 278 |
GO:1904951111 | Esophagus | ESCC | positive regulation of establishment of protein localization | 216/8552 | 319/18723 | 1.01e-15 | 6.86e-14 | 216 |
GO:0051222111 | Esophagus | ESCC | positive regulation of protein transport | 204/8552 | 303/18723 | 1.56e-14 | 8.38e-13 | 204 |
GO:0031334111 | Esophagus | ESCC | positive regulation of protein-containing complex assembly | 166/8552 | 237/18723 | 2.06e-14 | 1.07e-12 | 166 |
GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
GO:0030522110 | Esophagus | ESCC | intracellular receptor signaling pathway | 170/8552 | 265/18723 | 8.58e-10 | 2.09e-08 | 170 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NR1H2 | SNV | Missense_Mutation | | c.796N>T | p.Arg266Cys | p.R266C | P55055 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A08Z-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
NR1H2 | SNV | Missense_Mutation | rs140558724 | c.643N>A | p.Glu215Lys | p.E215K | P55055 | protein_coding | tolerated(0.74) | benign(0.029) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NR1H2 | SNV | Missense_Mutation | rs750204613 | c.376N>T | p.Arg126Trp | p.R126W | P55055 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-C8-A12M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NR1H2 | SNV | Missense_Mutation | | c.1049A>T | p.Asn350Ile | p.N350I | P55055 | protein_coding | deleterious(0) | possibly_damaging(0.881) | TCGA-E2-A15E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
NR1H2 | SNV | Missense_Mutation | | c.253N>A | p.Glu85Lys | p.E85K | P55055 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NR1H2 | SNV | Missense_Mutation | rs763608025 | c.788N>A | p.Arg263His | p.R263H | P55055 | protein_coding | tolerated(0.1) | benign(0.086) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NR1H2 | SNV | Missense_Mutation | | c.254N>C | p.Glu85Ala | p.E85A | P55055 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NR1H2 | SNV | Missense_Mutation | rs771140870 | c.341N>A | p.Ser114Asn | p.S114N | P55055 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MA-AA43-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
NR1H2 | SNV | Missense_Mutation | | c.659C>T | p.Thr220Ile | p.T220I | P55055 | protein_coding | deleterious(0.02) | benign(0.302) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
NR1H2 | SNV | Missense_Mutation | rs772224466 | c.67N>A | p.Ala23Thr | p.A23T | P55055 | protein_coding | tolerated(0.76) | benign(0) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135651470 | DESMOSTEROL | |
7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 223366058 | | |
7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | GW3965 | CHEMBL59030 | 18800767 |
7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135651391 | | |
7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | DESMOSTEROL | DESMOSTEROL | 23910990 |
7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135650496 | | |
7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | VTB-38543 | | |
7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | 135651390 | | |
7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | CHEMBL3545418 | BMS-779788 | |
7376 | NR1H2 | NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | agonist | CHEMBL3545238 | CS-8080 | |